Trial Profile
A Phase 1, Open-Label, Randomized, Single Dose, 5-Period, 5-Treatment Study to Evaluate the Relative Bioavailability and Effect of Food on TAK-831 Tablet Formulations in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jun 2021
Price :
$35
*
At a glance
- Drugs Luvadaxistat (Primary)
- Indications Ataxia; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Neurocrine Biosciences; Takeda Oncology
- 07 Jan 2019 Status changed from recruiting to completed.
- 25 Oct 2018 Planned End Date changed from 15 Dec 2018 to 22 Dec 2018.
- 25 Oct 2018 Planned primary completion date changed from 15 Dec 2018 to 22 Dec 2018.